Korro Bio's OPERA platform offers precise RNA editing for genetic diseases like Alpha-1 antitrypsin deficiency. Learn more on ...

The FDA clears Beam Therapeutics' investigational new drug application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency in the United States.

Beam Therapeutics BEAM has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives ...

As previously reported, BofA analyst Alec Stranahan upgraded Beam Therapeutics (BEAM) to Buy from Neutral with an unchanged price target of $42 ...

Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") of a class action securities ...

Beam Therapeutics (BEAM) announced that the FDA has cleared the investigational new drug application for BEAM-302 for the treatment of alpha-1 ...

The field of gene editing recently got a major boost from Massachusetts-based Beam Therapeutics, and the company’s Durham ...

Wave Life Sciences Ltd. shares promising updates on AATD & DMD treatments. Click here for my updated look at WVE stock ...

He convinced Manpreet to get a sample of Caleb's blood as he claimed that he had Alpha-1 antitrypsin (AAT) deficiency, and it ...

Wave Life Sciences Ltd.’s WVE share price has dipped by 10.08%, which has investors questioning if this is right time to buy.

The startup is using CRISPR tools to stop errant expression of a gene linked to facioscapulohumeral muscular dystrophy, a disorder on the radars of several drugmakers.

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) have earned an average recommendation of “Moderate Buy” from the nineteen research firms that are currently covering the firm, ...